Clinical Research Directory

Inclusion Criteria: 1. Aged 18 to 70 years; 2. Diagnosis of HCC with BCLC stage B/C; 3. Anticipated survival time is longer than 3 months; 4. Liver function grade Child-Pugh A or B, without hepatic encephalopathy; 5. Left ventricular ejection fraction (LVEF) ≥ 50%; 6. ECOG physical status 0-2; 7. Laboratory tests at baseline meet the following: Absolute neutrophil count \>1.0 x 109/L; Absolute neutrophil count \>1.0 x 109/L; White blood cell count \> 2.0 x 109/L; Platelet count \> 60 x 109/L; Hgb \> 8.0 g/dL; ALT and AST ≤ 5 times the upper limit of normal (ULN), Serum total bilirubin (TBiL) ≤ 51 mmol/L, or \< 3 times the ULN. 8. Female subjects of childbearing potential must take acceptable measures to minimize the likelihood of pregnancy during the trial. Female subjects of childbearing potential must have a negative serum or urine pregnancy result within 48 hours prior to treatment; 9. Able to receive treatment and follow-up, including the need for the subject to receive treatment at the enrollment center. Exclusion Criteria: 1. Pregnant or breastfeeding women; 2. WIth HIV/AIDS infection; 3. Active infection with a temperature \>38.3°C prior to study treatment and have been treated with antibiotics within 2 weeks prior to enrollment; 4. Presence of the following pre-existing or concomitant diseases: Prior diagnosis of a severe autoimmune disease requiring systemic immunosuppression (steroids) for a prolonged period of time (more than 2 months), or immune-mediated symptomatic disease; Prior diagnosis of autoimmune-induced motor neuron disease; Prior toxic epidermal necrolysis release; Subjects with any psychiatric condition, including dementia, altered mental status, which may interfere with treatment in this study; Subjects with other malignancies in the previous 5 years; Subjects with heart failure ≥ grade 2 (NYHA) or hypertension uncontrolled by standard therapy; Subjects with unstable or active peptic ulcer or gastrointestinal bleeding; Subjects with serious uncontrollable disease, as determined by the study, that may interfere with treatment in this study; 5. Subjects undergoing treatment with systemic steroids; 6. Subjects who have previously used immune cell therapy (CIK, DC, DC-CIK, LAK therapy) and are less than 28 days from the end of treatment to screening; 7. Subjects who are allergic to cell therapy products or related drugs; 8. Subjects who have previously received an organ transplant or are planning to receive an organ transplant; 9. Subjects requiring anticoagulant therapy (warfarin or heparin); 10. Subjects who are judged by the investigator to be unsuitable for participation in this study due to other conditions.